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Functional expression of catalytic antibodies in the cytoplasm of E. coli is potentially
of great interest in searching for new catalysts by genetic selection. Herein, a cata-
lytic antibody single chain Fv (ScFv) 14D9, which catalyzes a highly enantioselective
protonation, was expressed as a NusA fusion protein under the T7 promoter. A func-
tional disulfide-containing ScFv fusion protein was obtained in the oxidizing envi-
ronment of bacterial cytoplasm. The 14D9 ScFv could not be overexpressed alone
without NusA fusion. The highly soluble NusA protein most likely retards aggregate
formation of ScFv and indirectly supports correct folding and disulfide bridge forma-
tion in the fusion construct ScFv-NusA. The ScFv-NusA fusion product shows highly
enantioselective, specific, hapten inhibited catalytic activity comparable to its parent
monoclonal antibody, 14D9. The NusA fusion method might be generally helpful for
functional antibody expression in vivo and for the new development of biocatalysts
by genetic selection.
Key words: catalytic antibody; cytoplasmic expression; enantioselectivity; single
chain Fv; NusA.
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Recombinant antibody fragments are the workhorses of
antibody research since they offer a convenient format
for mutational manipulation of their sequences and func-
tional specificities (1). Although all antibodies have a
common framework and thus possess very similar struc-
tures, their expression in recombinant format is not uni-
form and must be optimized on a case by case basis, some
of which yield very respectable expression levels (2).
Available expression formats include the periplasmic
expression of Fab-fragments (3), which may be human-
ized (2), the single-chain Fv format (ScFv) (4), and the
helix-stabilized format (5). In relation to our interest in
the development of catalytic antibodies (6–7), we have
been particularly interested in finding a general format
for the cytoplasmic expression of functional antibody
fragments (8). Indeed such a format would make it possi-
ble to establish genetic selection schemes for the optimi-
zation of catalytic function by working on the catalysis of
reactions essential to cell survival, such as the liberation
of an essential growth factor from an inactive precursor,
or the catalysis of a metabolically essential reaction
within an auxotrophic host (9, 10).
Herein we report a novel method for the production of
a functional ScFv fragment in the oxidizing bacterial
cytoplasm. The system is demonstrated by the catalytic
antibody 14D9, a catalytic antibody against piperidinium
hapten 1a (11), which catalyzes the highly enantioselec-
tive protonation of enol ethers such as 2 to give optically
pure carbonyl products such as (S)-ketone 3 (12), with
constants for the reaction (kcat/kuncat = 104, kcat = 0.4 s–1 at
pH6.0) make it one of the fastest and most practical cata-
lytic antibodies reported to date (15). The ScFv-fragment
is fused with the NusA protein (N utilization substance
protein A), which shows the highest solubility in E. coli
(16). A stain bearing a defect in the reductase for thiore-
doxin and glutathione, which has been shown to accumu-
late active oxidizing enzymes in the cytoplasm (17), pro-
vides a potentially favorable environment for disulfide
bond formation of single chain Fv. We show that the com-
bination of NusA fusion and an oxidizing cytoplasmic
environment facilitates the expression of a functional
catalytic antibody fragment.
MATERIALS AND METHODS
Construction of Single Chain Fv 14D9—The Fd and
kappa chain gene fragments of 14D9 were amplified by
PCR as described (18). Amplified PCR products were
digested with XhoI-SpeI for the Fd gene fragment and
SacI-XbaI for the kappa chain gene fragment, and ligated
into phage display vector pcomb3H (19) to give pcomb3H-
14D9. All PCRs were carried out with Vent proof-reading
polymerase (New England Biolabs) to ensure the highest
fidelity. The VL and VH domains were PCR amplified
with primer pairs, VL_Bn 5-GCGGCCAGCGAGCTCGT-
GACACAGTC-3 and Linker_rev 5-GAACCTTCAGAGC-
TTTTGCCGCTACCGGAAGTGCTGCCTTTGATCTCAAG-




site is underlined) for the VH fragment. Single chain Fv
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pET43.1a (Novagen, Bad Soden, Germany) was digested
with SmaI-XhoI. The large fragment was purified from
an agrose gel and dephosphorylated by shrimp alkaline
phosphatase to minimize the ligation background. After
treatment with SalI, the amplified ScFv gene fragment
was inserted into pET43.1a by half-blunt end ligation to
give pET-14D9nus. A new PCR amplification was done
with VL53 5-GCAGTGACATATGGAGCTCGTGATGAC-
ACAGTCTCC-3 (the NdeI site is underlined) instead of
VL_Bn. The plasmid pET43.1a was digested with NdeI–
XhoI, the large fragment purified from an agrose gel was
ligated with an amplified ScFv fragment treated with
NdeI–SalI to give plasmid pET-14D9. Both clones were
confirmed by DNA sequencing.
Cytoplasmic Expression and Purification—BL21(DE3)
TrxB–,Gor–, under the name of Origami™, and strain
BL21(DE3), are available from Novagen. The procedures
for growth of the bacteria and induction of single chain
Fv were conducted according to a standard protocol.
Briefly, an overnight preculture grown in LB medium
supplemented with responding antibiotics [50 g/ml
Carbenicillin, 35 g/ml Kanamycin, and 15 g/ml Tetra-
cycline for BL21(DE3) TrxB–,Gor– ; 50 g/ml Carbenicil-
lin for BL21(DE3)] was incubated in 1 liter of the same
medium at 1:500 dilution and grown until mid exponen-
tial stage (A600 = 0.5) at 22C. Induction was started by
adding isopropyl thio--D-galactoside (IPTG) to the cul-
ture at a final concentration of 1mM, and growth was
continued for 15 h at 22C. The cells were pelleted, resus-
pended in lysis buffer (Tris 20 mM pH 8.0, 300 mM NaCl,
10 mM imidazole), and the cytoplasmic proteins were
extracted from the cells by sonication and subsequent
centrifugation. The supernatant was loaded onto a Ni2+-
NTA (IMAC) column (Qiagen), and the column was
washed extensively with washing buffer (20 mM Tris/
HCl, 300 mM NaCl, 40 mM imidazole pH 8.0). The fusion
ScFv was eluted with elution buffer (20 mM Tris/HCl,
300 mM NaCl, 250 mM imidazole pH 8.0).
ScFv Preparation from the Fusion Protein—The fusion
protein in PBS buffer (pH7.4) was digested with
Thrombin protease (Roche) for 12 h at 22C. The ratio of
fusion protein to protease was optimized and set to 0.5
unit/mg protein, and the protease-treated solution was
loaded directly onto the Ni2+-NTA column. The pass-
through was fed onto a hapten affinity column, in which
the hapten was coupled covalently to DEAE-Sepharose
(Pharmacia) (20). The column was washed with the same
buffer and the ScFv was eluted with 0.2 mM Glycine/
HCl, pH3.0, and immediately neutralized with 1M Tris/
HCl, pH 9.0. The eluate was dialyzed against PBS buffer
(pH7.4) overnight at 4C and concentrated with Cen-
triprepTM YM-10 and YM-30 (Amicon, Millipore).
The integrity of the recombinant fusion ScFv and its
purification were checked by SDS/PAGE on a homogene-
ous 15% gel with Coomassie Brilliant Blue staining. The
final protein concentrations were measured by UV spec-
trophotometry with extinction coefficient A280 = 1.35
cm2·mg–1.
Catalytic Activity Assay—Catalytic reactions were car-
ried out by mixing 0.6 l of a 10 mM stock solution of sub-
strate 2 in acetonitrile/water 1:1 (Fig. 1) with 19.2 l pro-
tein solutions at a concentration of 1 mg/ml in PBS
(pH7.4) at 22C (final concentration of 2: 300 M). An
identically prepared solution containing 0.2 l of 5 mM
inhibitor 1b (final concentration: 50 M) was used to
check specific inhibition. All reactions were monitored by
HPLC. The substrate and product were separated on an
analytical RP-C18 column (218TP54, 22 cm  0.45 cm,
300 Å poresize, Vydac, USA). Retention times were as fol-
lows (eluent: 1.5 mL.min–1 H2O/acetonitrile = 75:25,
detection by UV at 230nm): tR(2) = 3.3 min, tR(3) = 15.7
min. The percentage conversion as indicated in Fig. 3 was
calculated from peak integration.
Enantioselectivity Assay—Substrate 2 was incubated
with the antibody samples as above on a 200 l scale. The
entire reaction mixture was injected onto RP-C18-HPLC
and the product ketone 3 peak was collected and lyophi-
lized. The residue was taken up in hexane/isopropanol =
1:1, and analyzed on a chiral-phase column (Chiralpak
OD, Daicel, 22 cm  0.45 cm), which allows the separation
of the two enantiomeric products (eluent: hexane/isopro-
panol = 7:3; 1ml/min) as tR[(R)-3 = 8.6 min, tR(S)-3] = 12.4
min. The absolute configuration of the products was
established earlier by chemical correlation (21).
RESULTS
The antibody 14D9 Fab domain was cloned from the
14D9 hybridoma cell line (Details of the hapten-affinity
column preparation and use will be described elsewhere).
To assemble the two variable domains, we used a known
modified 18-amino acid linker derived from the classical
Gly-Ser linker, including three charged residues (Lys,
Lys, Glu) to enhance the solubility of the ScFv construct
(Details of the hapten-affinity column preparation and
use will be described elsewhere). The assembled ScFv
was cloned into the vector pET43.1a downstream of
NusA, separated by a histidine tag (6) and a 2–amino
acid spacer containing a thrombin cleavage site.
Fig. 1. Enantioselective protonation catalyzed by antibody
14D9.J. Biochem.
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chia Coli cells BL21(DE3), TrxB–,Gor–, which have an
oxidizing cytoplasmic environment favorable for the
expression of disulfide-bridged proteins (Details of the
hapten-affinity column preparation and use will be
described elsewhere). These cells grow quite slowly com-
pared to the BL21(DE3) wild type. After induction over-
night, the fusion protein was purified by Ni2+-NTA chro-
matography (IMAC). Two main bands were observed in
the reducing SDS-PAGE (Fig. 2, lane A), one correspond-
ing to a molecular mass of ca. 82 kDa, the other with a
relatively low molecular mass appearing close to NusA
(Fig. 2, lane C, theoretical mass of 54 kDa). Between
these two main bands, some smeared bands suggested
the degradation of unfolded fusion proteins; the second
main band (NusA) might be the remainder of such degra-
dation. The expression yield was calculated from total
elution from the IMAC and reached a satisfactory level of
3 mg/litre LB medium.
Purification of the ScFv-NusA construct by hapten-
affinity chromatography gave 14D9 ScFv and NusA in
equal amounts, this due to the cleavage by proteolytic
impurities during sample dialysis and concentration
after elution from the column. The 14D9 ScFv fragment
was, therefore, cleaved on purpose by treatment with
thrombin, for which a cleavage site is present in the 20–
amino acid linker between NusA and the ScFv, and puri-
fied by filtration through a Ni2+-NTA column followed by
hapten-affinity chromatography. The product isolated
showed only one band at 28 kDa, indicative of a high
purity and integrity (Fig. 2, lane E). The overall yield of
the expressed ScFv domain thus isolated from the NusA-
fusion protein amounted to 0.5 mg/liter LB medium. For
comparison, the 14D9 Fab fragment was prepared from
the hybridoma-produced monoclonal antibody by papain
digestion (25), and purified by hapten-affinity chroma-
tography.
The functionality of the 14D9 ScFv-NusA fusion pro-
tein and the cleaved 14D9-ScFv was compared to the
14D9-Fab fragment by testing the chemical catalysis of
the enantioselective protonation of enol ether 2 to pro-
duce ketone (S)-3, which can be recorded by HPLC (Fig.
1). The protein samples were tested at an equal concen-
tration of 1 mg/ml (as measured by optical density) at pH
7.4 in the presence or absence of the activesite-specific
hapten inhibitor 1b. All three samples catalyzed the for-
mation of ketone 3 to a comparable level. In all three
cases, the activity was quantitatively inhibited to the
background level in the presence of the 14D9-specific
hapten 1b. Chiral-phase column analysis of the ketone
formed showed that all three samples catalyzed the for-
mation of the S-enantiomer of ketone 3 exclusively, in
agreement with the absolute control of enantioselectivity
achieved by antibody 14D9 for this reaction (15), with the
amount of racemate present in the sample corresponding
to the level of the background reaction as calculated from
the hapten-inhibited reaction. To examine disulfide
bridge formation, the purified 14D9 ScFv-NusA and ScFv
were treated with 10 mM -mercaptoethanol before
activity measurement. There was a complete loss of
catalysis in the sample, indicating the importance of
disulfide bridges to functionality, and confirming that
correct disulfide bond formation occurred in the cyto-
plasm.
To investigate the solubilizing ability of the NusA pro-
tein, pET-14D9nus was transformed into BL21(DE3)
wild type, which should not support disulfide bridge for-
mation in the cytoplasm. The purified cytoplasmic
extract showed a pattern similar to the expression in oxi-
dizing cytoplasm, but with a very low relative depth ratio
of intact fusion protein to NusA (Fig. 2, lane B). In addi-
tion, the fusion protein band located at 82 kDa disap-
peared after storage overnight at 4C, indicating degra-
dation and structural instability due to the lack of
disulfide bonds in the reducing cytoplasm.
Fig. 2. Expression and purification of 14D9-ScFv NusA fusion
constructs. Lane A: 14D9 ScFv-NusA fusion protein expressed in
the cytoplasm of BL21(DE3) TrxB–, Gor– cells after purification
with IMAC. Lane B: 14D9 ScFv-NusA fusion protein expressed in
the cytoplasm of BL21(DE3) cells after purification with IMAC.
Lane C: NusA protein expressed in the cytoplasm of BL21(DE3)
cells after purification with IMAC. Lane D: Total cell extract for the
expression of 14D9 ScFv without NusA in BL21(DE3) TrxB–, Gor–
cells. Lane E: ScFv purified from a hapten affinity column after fil-
tration through a Ni2+-NTA column.
Fig. 3. Catalytic activity assay for 14D9 antibodies. Percent
conversion of enol ether 2 to ketone 3 is shown as a function of time.
Measured by peak integration of RP-HPLC. Conditions: 300 M
substrate 2 in aq. PBS with 1.5% v/v acetonitrile, 1 mg/ml protein,
25C. (solid square): catalytic reaction of 14D9 ScFv-nusA fusion
protein; (open square): inhibition of 14D9 ScFv-nusA fusion protein
with 50 M hapten 1b; (solid triangle): catalytic reaction of 14D9
Fab purified from hybridoma; (open triangle): inhibition of 14D9
Fab with 50 M hapten 1b; (solid circle): catalytic reaction of 14D9
ScFv cleaved from the 14D9 ScFv-nusA fusion protein; (open circle):
inhibition of 14D9 ScFv with 50 M hapten 1b.Vol. 133, No. 5, 2003
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ent on primary sequence (26), and the success obtained
with the NusA fusion construct might be entirely due to
the 14D9 itself. To test this point, the direct expression of
14D9-ScFv without NusA was also investigated. Thus,
the NusA 6x histidine tag and spacer were deleted, and
the 14D9-ScFv fragment was cloned downstream of the
T7 promoter to give plasmid pET-14D9. Expression of
this plasmid yielded most of the 14D9-ScFv as an inclu-
sion body, which was retained in the cytoplasmic pellet
even at low temperature (22C) (Fig. 2, lane D). Hapten
affinity chromatography gave only a tiny peak of ScFv
that was too small to be quantitated and isolated. These
experiments show that 14D9-ScFv alone is not expressed
in a functional soluble form, thereby highlighting the key
role of NusA-tag as a solubilizing agent for the antibody.
DISCUSSION
Antibody expression in recombinant format must be
appreciated from the point of view of functionality, con-
venience, and overall yield. Here we present the overex-
pression of a catalytic antibody fragment 14D9, which
accelerates an abiological, enantioselective protonation
reaction on synthetic substrate 2 with a rate enhance-
ment of kcat/kuncat = 104. This rate enhancement is very
good for an antibody, but by no means comparable to that
of an enzyme, and requires fair amounts of functional
protein to provide a signal in the HPLC assay used for
activity detection. Considering that the activity appears
in direct proportion to the amount of functional protein
and that there is no possibility for signal amplification as
is possible with ELISA-type activity tests, the evidence
for functionality presented here can be considered as par-
ticularly strong. The evidence is reinforced by the obser-
vation of the specific inhibition of activity by the small
molecule hapten 1b in all cases, to the extent of the enan-
tioselectivity measured by chiral phase HPLC analysis of
ketone 3. It must also be mentioned that the catalysis of
this enantioselective process by enzyme impurities is
highly improbable as the enol ether functional group is
virtually unknown in natural products, and no enzymes
are known that catalyze this reaction type.
As for convenience, the cloning procedure used to con-
struct the 14D9-ScFv NusA fusion vector from the 14D9
hybridoma cell line involved only a minimal set of stand-
ard operations. Purification of the expressed fusion pro-
tein by simple IMAC using the His-tag provided an anti-
body sample of sufficient purity for activity detection.
Remarkably, the 14D9-ScFv fragment is not expressed in
a soluble functional form when expressed alone within
the oxidizing cytoplasm of E. coli BL21(DE3), TrxB–,
Gor–, but appears almost exclusively as insoluble inclu-
sion bodies. While the ScFv-NusA fusion product is
formed in a stable form under these conditions, expres-
sion in the wild-type reducing cytoplasm provided only
an unstable product that was quickly degraded. These
results suggest that NusA proteins act as solubilizing
agents, which allows the ScFv fragment to properly fold
without forming insoluble aggregates. However, proper
folding is tied to the formation of the structurally essen-
tial disulfide bridges. Indeed the rapid degradation of the
ScFv portion of the fusion construct under the reducing
wild-type conditions suggests that ScFv is not properly
folded under these conditions, but yet remains in a solu-
ble form and is, therefore, particularly vulnerable to the
action of proteases. To compare in vivo folding with the in
vitro refolding procedure, the 14D9 ScFv inclusion body
was refolded by two popular ScFv refolding protocols (31,
32). All attempts to refold failed, implying that some fac-
tors in the cytoplasm, probably chaperones, might facili-
tate the folding of ScFv in vivo. Our experiment with
antibody 14D9, whose ScFv fragment is not suited for
cytoplasmic expression, suggests that the NusA fusion
format should be easily transferable to other antibodies.
This NusA fusion method might be generally useful as an
alternative for functional antibody expression.
The calculated yield of 3 mg/liter of functional fusion
protein obtained lies well within the range accessible
without optimization for antibody expression systems.
The lower specific activity of the 14D9 ScFv-NusA fusion
protein compared with the purified 14D9Fab and 14D9
ScFv fragments is partly explained by its higher molecu-
lar mass, but is certainly also due to the fact that the pro-
tein purified by IMAC is not pure and contains NusA
from which the ScFv has been cleaved (Fig. 2), as evi-
denced by the fact that only 1.4 mg/liter of 14D9 ScFv-
NusA fusion protein was isolated after hapten-affinity
chromatography. The key point is that no refolding oper-
ation was undertaken to isolate an active sample of 14D9
ScFv-NusA fusion protein, and that the activity of this
sample establishes that the ScFv-NusA fusion protein is
indeed functional as expressed in the cytoplasm. While
this is not necessarily important for expression, it
becomes critical from the perspective of setting up a
genetic selection system to improve the catalytic effi-
ciency of antibodies. Indeed, selection schemes based on
metabolic selection are envisioned as the best approach
Fig. 4. Enantioselectivity assay for 14D9 antibodies. The peak
of product ketone 3 from the analytical RP-C18 column was col-
lected and lyophilized, and the residue taken was up in hexane/iso-
propanol = 1:1, and analyzed on a chiral-phase column (Chiralpak
OD, Daicel, 22 cm  0.45 cm), which allows the separation of the two
enantiomeric products (eluent: hexane/isopropanol=7:3; 1 ml/min)
as tR(R)-3 = 8.6 min, tR(S)-3 = 12.4 min. (A) racemic ketone 3 pro-
duced by treatment of enol ether 2 with 0.1% TFA, R/S = 49%/51%.
(B): (S)-ketone 3 from the reaction with 14D9-Fab, R/S = 6%/94%;
(C): (S)-ketone 3 from the reaction with 14D9 ScFv-nusA fusion pro-
tein, R/S = 8%/92%; (D): (S)-ketone 3 from the reaction with 14D9
ScFv protein, R/S = 3%/97%.J. Biochem.
A Potential Catalytic Antibody Genetic Selection System 581to improve the activity of catalytic antibodies over rounds
of mutation and selection. Cytoplasmic expression of
functional antibodies is particularly important in that
respect as most genetic selection schemes should involve
the catalysis of chemical reactions taking place within
the cytoplasm, such as the catalysis of key metabolic
reactions (11, 12) or the liberation of essential growth
factors from synthetic precursors. Catalytic antibody
14D9 has been shown to catalyze a variety of processes,
such as epoxide and acetal hydrolysis (12, 27–30). Some
of these might be amenable to the release of an essential
growth factor, for example biotin, from a specifically syn-
thesized substrate, and future experiments will address
this point.
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